VX509: They never really went further into detail on ph2a trial result, at least I am not aware of it. Lots of question to me. I discussed this before on this board comparing their result with PFE's pan-JAK, LLY/INCY's JAK1/2 at similar stage, VX509 safety profile was worse. I did put qualifier here regarding wider dose range used in VX509 ph2a trial:
They are doing ph2b trial, plus MRI trial on disease modifying activities right now. Result 2H this year. These two trials will determine its value, if any. I don't give much value to it myself. Neither does the market IMO.
Market Data 
Markets 
AI
